Cerlapirdine
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.[1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events,[2] but no further development has occurred since 2011.[3]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H23N3O3S |
| Molar mass | 409.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It exerts its effects by acting as a selective 5-HT6 receptor antagonist.[1]
See also
References
- Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi:10.1016/j.coph.2011.01.004. hdl:10171/18451. PMID 21330210.
- Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN 978-0-12-385902-0. Retrieved 25 October 2011.
- Drug Profile: Cerlapirdine
| AChE inhibitor medications | |
|---|---|
| Other medications | |
| Experimental BACE inhibitors | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.